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The present study aimed to investigate the analgesic eﬀect of JCM-16021, a revised traditional Chinese herbal formula, on
postinﬂammatoryirritablebowel syndrome(PI-IBS)inrats.Thetrinitrobenzene sulfonic(TNBS) acid-induced PI-IBSmodel rats
were orally administrated with diﬀerent doses of JCM-16021 (1.2, 2.4, and 4.8g/kg/d) for 14 consecutive days. The results showed
thatJCM-16021treatment dose-dependently attenuated visceral hyperalgesia inPI-IBSrats.Further,thecolonic enterochromaﬃn
(EC) cell number, serotonin (5-HT) content, tryptophan hydroxylase expression, and mechanical-stimuli-induced 5-HT release
were signiﬁcantly ameliorated. Moreover, the decreased levels of mucosal cytokines in PI-IBS, especially the helper T-cell type 1-
(Th1-) related cytokine TNF-α, were also elevated after JCM-16021 treatment. These data demonstrate that the analgesic eﬀect of
JCM-16021 on TNBS-induced PI-IBS rats may be medicated via reducing colonic EC cell hyperplasia and 5-HT availability.
1.Introduction
Irritable bowel syndrome (IBS), one of the most frequently
reported functional disorders of the gastrointestinal tract,
is characterized by chronic abdominal pain, and alterations
in bowel habits. Clinically, there is a subset of IBS patients
termed as postinfectious or PI-IBS; in these patients, IBS
symptoms occur after an initial episode of acute gastroin-
testinal infection. The major clinical features of PI-IBS
include loose stool with urgency, accelerated colonic transit,
and decreased pain threshold, which are similar to those
of diarrhea-predominant IBS (IBS-D) [1, 2]. Epidemiologic
studies showed that IBS aﬀects 5–10% of the populations,
and IBS-D is reported as the most frequent subtype [3].
Prospective studies also showed that 3–36% of enteric
infections may lead to the generation of new IBS symptoms.
In recent years, more attention has been paid to PI-IBS
because it is believed that the clear onset and well-deﬁned
pathophysiological changes will help us understand not only
the PI-IBS but also other subtypes of IBS [4].
Visceral hypersensitivity is the leading hypothesis to
explain painful symptoms suﬀered by IBS patients, although
the mechanism is not fully understood [5–7]. Enterochro-
maﬃn (EC) cell hyperplasia and serotonin (5-HT) hyperac-
tivityhavebeenreportedtoplayimportantrolesinthedevel-
opment of visceral hypersensitivity in IBS patients [8–11],
especiallyinIBS-Dpatients[12].Asanintercellularsignaling
molecule, 5-HT activates intrinsic and extrinsic primary
afferent neurons, therefore, regulates the gastrointestinal
sensitivity [13]. It has been reported that 5-HT excited
nociceptiveaﬀerentsandinducedhypersensitivityinhumans
and rats through activating peripheral 5-HT2A and 5-HT32 Evidence-Based Complementary and Alternative Medicine
receptors [14–16]. Previous studies also showed that 5-HT
potentiated visceral hypersensitivity by sensitizing certain
peripheral transient receptor potential vanilloid (TRPV)
function, such as TRPV1 and TRPV4, which are all critical
integrators of various nociceptive stimuli [17–19]. Given the
important role of 5-HT in developing and maintaining
visceralhypersensitivity, 5-HT signalling pathwayshavebeen
considered as a promising target for IBS treatment.
Itiswellknownthatabout95%ofthetotal5-HTisfound
in the gastrointestinal tract, with 90% in EC cells [20]. The
rate-limiting enzyme of 5-HT synthesis, tryptophan hydrox-
ylase (TPH), is found mainly located in EC cells [21]. In
addition,ECcellshavebeenregardedastheintestinalsensors
that detected chemical, mechanical, or pathological stimuli
in the lumen [22]. Following mucosal stimulation, 5-HT
is quickly released from EC cells and activates serotonergic
receptors located on nerve ﬁbers. The actions of released 5-
HT are terminated via being uptaken into the enterocytes by
serotoninreuptaketransporter(SERT)[23].BecauseECcells
are the major cell type responsible for the synthesis, storage,
and release of 5-HT in the gut, the number and function of
EC cells play the important roles in intestinal homeostasis.
Up to now, EC cell hyperplasia has been identiﬁed in a
number of intestinal infections induced by bacteria, virus,
and parasites [24–26], including PI-IBS patients [1, 27],
but the underlying mechanisms remain unclear. Recently,
studies on the linkage between EC cells and immune system
showed that CD4+ T cells played an important role in the
development of colonic EC cell hyperplasia in intestinal
infection, and EC cells were inﬂuenced by helper T-cell
subtype 1 (Th1) or subtype 2 (Th2) cytokine predominant
environments [28, 29]. It has been proposed that any alter-
ations in 5-HT availability, such as biosynthesis, release, or
uptake, may contribute to the disordered gastrointestinal
sensation and motility. Therefore, therapeutic strategies
basedon5-HTsystemhavebeenstudiedextensively[30,31].
Nowadays, TPH inhibitor, 5-HT3 receptor antagonists, and
5-HT4 receptoragonistshavebeenappliedtotreatfunctional
gastrointestinal disorders [21, 32].
Though IBS seems not lead to more serious conditions
in most patients, the multiple and persistent symptoms con-
tribute to the high work absenteeism, high socioeconomic
burden, and decline of life quality [33, 34]. Unfortunately, to
date, there are not satisfactory treatments for IBS suﬀerers.
The managements primarily aim at symptomatic relief [4,
35]. It is reported that only 14% of patients with IBS are
completely satisﬁed with their current therapy [36, 37].
With the unsatisfactory treatment responses of western
medicines, many IBS suﬀers turn to alternative treatment
modalities, such as traditional Chinese medicine (TCM), ac-
upuncture, qi-gong, and mind-body therapy [37, 38]. JCM-
16021, a Chinese herbal formula composed of seven herbs, is
modiﬁed based on a traditional formula (Tongxie Yaofang)
for diarrhea and abdominal pain. In a randomized, double-
blinded, and placebo-controlled trial, JCM-16021 has been
proved to relieve symptoms in IBS patients [39]. Results
from our previous studies also showed that JCM-16021
dose-dependently attenuated neonatal maternal separation-
induced visceral hyperalgesia in rats through reducing
colonic 5-HT synthesis and metabolism [40]. Whether JCM-
16021 is beneﬁcialfor PI-IBS-related symptoms has not been
investigated.
The present study hypothesized that JCM-16021 can
attenuate visceral hyperalgesia in TNBS-induced PI-IBS
rats, and the underlying mechanism may be mediated via
reducing colonic EC cell hyperplasia and 5-HT availability.
According to the results from our previous systematic review
[41], the TNBS-induced PI-IBS rat model was used in this
study. The PI-IBS rats were orally treated with JCM-16021
for 14 consecutive days, and then visceral sensation, EC cell
number, 5-HT content, SERT, and TPH expression were
investigated.Inaddition,mucosalcytokineproductionswere
also investigated in order to identify whether there is an
alterationinmucosalcytokineproductionofPI-IBSrats,and
whether JCM-16021 has aﬀect on it.
2.MaterialsandMethods
2.1. Materials. 2,4,6-trinitrobenzenesulfonic acid (TNBS),
parachlorophenylalanine (pCPA), sodium hyposulﬁte, and
silver nitrate were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Chloral hydrate was purchased from Kou Hing
Hong Scientiﬁc Supplies (Hong Kong, China). TNF-α,I F N -
γ, IL-6, and IL-10 ELISA kits were purchased from eBios-
cience (San Diego, USA). The raw materials in JCM-16021
were all examined according to the quality control criteria of
Chinese Pharmacopeia 2005 and controlled as previous
report [40]. JCM-16021 granules were prepared as follows:
raw materials at the total amount of tenfold of one day’s
dosage of JCM-16021 were mixed and macerated for 30min,
then decocted for 40min for two times. The decocted
solution was combined and precipitated in 65% ethanol for
16h.Theﬁltrateswereﬁnallydriedinavacuumat70◦C.The
extraction eﬃciency of JCM-16021 granules was calculated
according to the content of paeoniﬂorin, one of the active
ingredients in JCM-16021.
2.2.AnimalsandInductionofPI-IBSModel. Sprague-Dawley
male rats (aged 6 weeks with body weight around 220g)
were obtained from the Laboratory Animal Services Centre,
The Chinese University of Hong Kong. Rats were maintained
at 25◦C under 12h-12h alternating light-dark cycle. Before
colitis induction, rats were allowed to adapt the environment
for 1 week. The PI-IBS rat model was developed according to
previousreport[42].Brieﬂy,afterfastedfor24hours,therats
were deeply anesthetized with chloral hydrate (350mg/kg,
i.p.). A plastic catheter (external diameter = 0.96mm) was
inserted into the descending colon at the depth of 8cm
from anus, then TNBS (5mg/rat, 0.8mL in 50% ethanol)
saline solution was instilled slowly. The control group was
treated with 0.8mL saline instead of TNBS. After TNBS
or saline administration, the rats were left on a mound of
bedding in head-down position to prevent drug leakage. At
4 weeks after TNBS administration, visceral pain threshold
pressure was measured. The rats with acquired visceral
hyperalgesia (pain threshold pressure below 30mmHg) were
selected as the PI-IBS rats. All studies were carried out inEvidence-Based Complementary and Alternative Medicine 3
accordance with the guidelines of the Committee on Use
of Human and Animal Subjects in Teaching and Research,
Hong Kong Baptist University.
2.3. Experimental Design. The ﬁrst series of experiments
aimed to test whether JCM-16021 can attenuate visceral
hyperalgesia in TNBS-induced PI-IBS rats. Six groups of 12
rats were used. The PI-IBS rats were randomly divided into
5 groups and treated with water (Group 1), pCPA (TPH
inhibitor, 150mg/kg/d∗3d, i.p., Group 2), and JCM-16021
(Group 3–5) at the dose of 1.2, 2.4, and 4.8g/kg/d; and the
normal control (Group 6) were treated with water. After 2
weeks treatment, 5 rats in each group were used to measure
pain threshold pressure, and the rest of the rats were used for
electromyography recording. In pCPA-treated group, pain
threshold pressure was measured at 3 days after pCPA
administration. Subsequently, the rats were sacriﬁced for
sample collection. A 6cm long proximal colon (1-2cm from
caecum) was harvested and divided into 3 parts, the
proximal was ﬁxed in 4% paraformaldehyde and embedded
in paraﬃn; the middle part was collected for 5-HT content
measurement and electron microscopic evaluation; the distal
part was for western blotting analysis. The transverse colon
mucosa was also collected for cytokine assay.
The second series of experiments aimed to evaluate the
eﬀects of JCM-16021 on EC cell hyperplasia, 5-HT synthesis,
and5-HTreleaseinPI-IBSrats.Sixgroupsof5ratswereused
in this experiment, and the group setting and treatments
were as same as that of the ﬁrst series of experiments. Diﬀer
from that of the ﬁrst series of experiment, AWR test was
not applied in order to obtain the baseline data that without
colorectal distension (CRD) stimulus. The samples were
collected and processed as same as that described in the ﬁrst
series of experiments.
2.4. Abdominal Withdrawal Reﬂex (AWR). AWR test was
performed as previously described [43]. Brieﬂy, rats were
lightly anesthetized with ether, then a 6cm-long ﬂexible
latex balloon was inserted into the descending colon. The
end of the balloon was secured at least 1cm proximal to
the anal verge. Rats were then allowed to recover for about
1h, and colorectal distension was applied in increments of
5mmHg until a visible contraction of the abdominal wall
was observed by an investigator blinded to the treatment.
The pain threshold pressure was deﬁned as the intensity of
colorectal distension that elicited an observable AWR, that is,
a sudden and persistent abdominal muscle contraction with
abdomen lift oﬀ the platform (Score 3). The pain threshold
pressures of all groups were repeated ﬁve times with intervals
of at least 5 minutes for recovery.
2.5. Electromyography (EMG) Recording. To evaluate the
effects of JCM-16021 on visceral hyperalgesia in PI-IBS rats,
visceral motor response to CRD was also applied in this
study, and the experiment was conducted as previously
described [44, 45]. Firstly, a surgical operation was made
to implant the electrodes into the left external abdominal
oblique muscles at 7 days before EMG recording. After
the ﬁnal drug administration, a ﬂexible latex balloon was
inserted into the rat descending colon, and the rats were
allowed to accommodate for 1h. Colorectal distension was
initiated, and the EMG signal was ampliﬁed and ﬁltered by
Power Lab System. Graded colorectal distension (20, 40, 60,
and 80mmHg; 20s duration; 2min interstimulus interval)
was carried out for total three cycles to each rat. The changes
of area under the curve (AUC) were calculated using that
during 20s distension period over the 20s baseline.
2.6. EC Cell Counting. Tissue sections (5μm thick) were de-
parafﬁnized and rehydrated for silver staining according to
a method previously described [46]. Brieﬂy, sections were
incubated with 5% ammoniacal silver solution for 4h at
r o o mt e m p e r a t u r e ,t h e n2hi n5 6 ◦C and subsequently 12h
at room temperature in a dark humidiﬁed chamber. After
rinsing with water, 5% sodium hyposulﬁte was added and
i n c u b a t e df o r5 m i na tr o o mt e m p e r a t u r e .T h eb r o w nt o
black silver precipitates in the cytoplasm of EC cells were
considered as a positive reaction. Five random ﬁelds at 200x
magniﬁcations were counted in each section by a researcher
blinded to the treatment; the number of EC cells per mm2 of
mucosa was quantiﬁed using Image J NIH software.
2.7. 5-HT Assessment. 5-HT content in the colon tissue was
assayed followed by our previously reported procedure [47].
Brieﬂy, the colon segments were homogenized in 15% iced
trichloroacetic acid for 2min and stored at 4◦Cf o r2h .A f t e r
centrifuge at 10,000G for 15min, the supernatant of each
sample was ﬁltered through 0.22μm ﬁlter and extracted with
diethyletherforﬁvetimes.Thepreparedsampleswereadded
to derivatization solution (150mM sodium tetraborate, 25%
acetonitrile, 2mM CFSE) and incubated for 30min at
room temperature in dark. The 5-HT content was analyzed
by capillary electrophoresis with laser-induced ﬂuorescence
detection and expressed as nanogram per milligram (wet
weight of the tissue).
2.8. Western Blot Analysis. The colonic tissues were homoge-
nizedandsonicatedoniceforproteinextraction.Afterdeter-
mination of protein content, the samples were denatured at
100◦C for 5min. Proteins were separated by 10% SDS-PAGE
and transferred to PVDF membrane (Bio-Rad, CA). After
blocking with 5% nonfat milk, the membrane was incubated
overnight at 4◦C with rabbit anti-TPH antibody (1:1000,
Santa Cruz, CA), then incubated with the appropriate
secondary antibodies for 1h at room temperature. The
immunoreaction was detected using ECL Western blotting
kit (ECL, Amersham, UK). Bands were visualized on Biomax
X-ray ﬁlm, and the optical density of each band was
semiquantiﬁed by computer software (Image J.NIH). All
detected protein bands were normalized to β-actin levels.
2.9. Immunoﬂuorescence Staining for SERT. The tissue sec-
tions (6μm thick) were rinsed in PBS (pH. 7.4) and placed
in polycarbonate staining jars (Kartell, Italy) ﬁlled with
10mM sodium citrate buﬀer solution (pH. 6.0). After
15minmicrowaveexposureforantigenretrieval,nonspeciﬁc4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Eﬀects of JCM-16021 on visceral hypersensitivity of PI-IBS rats. (a) depicts the analgesic eﬀect of JCM-16021 in PI-IBS rats in
terms of pain threshold pressure, while (b) depicts the eﬀect of JCM-16021 on visceral motor response to graded CRD in PI-IBS rats. The
representative EMG graphs from normal rats, PI-IBS rats, and high-dose JCM-16021 treated rats in a 20s noxious (80mmHg) colorectal
distension period are shown in (c). Data are presented as mean ± S.E.M., n = 5p e rg r o u pi nA W Rt e s t ,n = 8 per group in EMG recording
test. #P < 0.05 versus normal rats,
∗P < 0.05, versus PI-IBS rats (t-test).
antibody binding was reduced by incubation of the tissues in
a solution of 3% bovine serum albumin, 0.5% Triton X-100
in PBS. Sections were incubated with rabbit anti-SERT poly-
clonal antibody (1:500, Calbiochem, CA) in PBS containing
0.5% Triton X-100 overnight at 4◦C. After rinsed in PBS,
the sections were incubated with Alexa ﬂuor 488-conjugated
secondary antibody (1:200, Invitrogen) for 2h at room
temperature, and then rinsed and coverslipped. Sections
were observed with a laser scanning microscope (Olympus
Fluoview FV1000), captured with 400x, and analyzed using
Image J NIH software. The optical densities in colonic
mucosa were measured after background subtracting. The
total SERT immunoﬂuorescence densities from 5 random
ﬁelds per section were calculated.Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀects of JCM-16021 on enterochromaﬃn (EC) cell density and 5-HT content in the colon tissue of PI-IBS rats. (a) shows the
representative EC cells (arrowhead) in colonic mucosa of the (A1) normal rats, (A2) PI-IBS rats, (A3) pCPA treated rats, and (A4) high dose
JCM-16021 treated rats (Scale bar, 200μm). Statistical graph of EC cell density is shown in (b), and 5-HT content in (c). Data are presented
as mean ± S.E.M., n = 5p e rg r o u p . #P < 0.05 versus normal rats,
∗P < 0.05,
∗∗P < 0.01 versus PI-IBS rats (t-test).
2.10. Electron Microscopic Evaluation. The colon segments
were ﬁxed for 24h at 4◦C in the ﬁxative containing 4%
paraformaldehyde and 0.2% picric acid in 0.1M PB then
washed and embedded in gelatin. Thin sections were cut
and picked up on the 200-mesh grids. The sections were
stained with uranyl acetate and lead citrate. Examination
and photography of sections were carried out using Philips
CM 10 transmission electron microscope (Philips Scientiﬁcs,
Netherlands). At the ultra-structural level, EC cells were
distinguished from other enteroendocrine cells by the pleo-
morphic nature of their secretory granules [48]. The EC cell
in which there were many clear secretory granules without
cores or granules with eccentric cores was considered as the
activated one with excessive 5-HT release [49].
2.11. ELISA Assay. The mucosal samples were lysed with Tris
EDTA (10mM Tris-HCl, 1mM EDTA, pH 7.4) containing
0.5% Triton X-100 and protease inhibitors, and then the
samples were homogenized and sonicated on ice. After
centrifuge at 10,000G for 10min at 4◦C, the supernatant was
collected and stored at −80◦C until use. Mucosal cytokine
levels of TNF-α,I F N - γ, IL-6, and IL-10 were determined6 Evidence-Based Complementary and Alternative Medicine
using ELISA kits according to the manufacturer’s protocol.
The results were expressed at pg/mg total protein.
2.12. Statistical Analysis. Data are presented as mean ±
S.E.M. Statistical analysis was conducted using SPSS 12.0
Software. Diﬀerences between two groups were analyzed
with Student t-test. When multiple groups were compared,
data were analyzed using one-way ANOVA followed by
Student-Newman-Keuls(SNK)test.Diﬀerenceswereconsid-
ered signiﬁcant when P<0.05.
3. Results
3.1. Analgesic Eﬀect of JCM-16021 in PI-IBS Rats. As shown
in Figure 1(a), the pain threshold pressures in PI-IBS rats
(TNBS + water treated rats) were signiﬁcantly decreased
when compared to that of the control (saline + water treated
rats, P<0.05). After pCPA treatment, the pain threshold
pressures in PI-IBS rats were signiﬁcantly elevated (P<
0.05), suggesting that 5-HT played an important role in the
development of visceral hypersensitivity. After JCM-16021
treatment, the pain threshold pressures were signiﬁcantly
and dose-dependently elevated when compared to that of
the PI-IBS rats (P<0.05), indicating that JCM-16021 has
analgesic eﬀect in PI-IBS rats. Consistent with the ﬁndings
from AWR test, the results from EMG recording (Figures
1(b) and 1(c)) also showed that visceral motor responses to
graded CRD in PI-IBS rats were signiﬁcantly increased when
compared to that of the control (P<0.05). After JCM-16021
treatment, the visceral motor responses to graded CRD in
PI-IBS rats were decreased signiﬁcantly in a dose-dependent
manner (P<0.05).
3.2. Eﬀects of JCM-16021 on Colonic EC Cell Number and 5-
HTContentinPI-IBSRats. AsshowninFigure2,thecolonic
EC cell density and 5-HT content were both signiﬁcantly
increased in PI-IBS rats (∼51% in EC cell density, ∼23%
in 5-HT content) when compared to that of the control
(P<0.05), suggesting the occurrence of EC cell hyperplasia
in PI-IBS rats. Compared with the PI-IBS rats, JCM-16021
treatment signiﬁcantly and dose-dependently decreased the
colonic EC cell density (20%∼48%) and 5-HT content (8%∼
26%) in PI-IBS rats, suggesting that JCM-16021 can reduce
colonic EC cells hyperplasia of PI-IBS rats. PCPA treatment
also signiﬁcantly decreased the colonic EC cell density and 5-
HT content in PI-IBS rats (∼57% in EC cell density, ∼62.5%
in 5-HT content, P<0.05).
3.3. Eﬀect of JCM-16021 on Colonic TPH Expression in PI-IBS
Rats. Given the important role of the rate-limiting enzyme
in 5-HT synthesis, colonic TPH expression was further
evaluated by Western blot technique. As shown in Figure 3,
TPH protein expression in PI-IBS rats was signiﬁcantly
increased(∼26%)whencomparedtothatofthecontrol(P<
0.05), while high-dose JCM-16021 treatment signiﬁcantly
reducedtheTPHexpressioninPI-IBSrats(∼36%,P<0.05).
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Figure 3: Eﬀect of JCM-16021 on colonic TPH expression in PI-
IBS rats. Western immunoblots of TPH and the statistical analysis
of protein level showed that JCM-16021 signiﬁcantly decreased the
colonic TPH expression in PI-IBS rats. Data are shown as mean ±
S.E.M., n = 4p e rg r o u p . #P < 0.05 versus normal rats,
∗P < 0.05
versus PI-IBS rats (t-test).
3.4. Eﬀect of JCM-16021 on Mucosal SERT Expression in
PI-IBS Rats. As shown in Figure 4, the intensity of SERT
immunoreactivity in colonic mucosa of PI-IBS rats was
signiﬁcantly decreased when compared to that of the control
(40.3 ± 3.1v e r s u s4 9 .0 ± 3.2; P<0.05), suggesting that
TNBS-induced PI-IBS rats also has the decreased SERT
expression in the colon. After treatment of JCM-16021, there
were no signiﬁcant diﬀerences in the expression of SERT
immunoreactive intensity between PI-IBS rats and JCM-
16021-treated rats (40.3 ± 3.1v e r s u s4 2 .6 ± 2.1; P<0.05),
suggesting that JCM-16021 treatment has little eﬀect on the
decreased SERT expression in PI-IBS rats.
3.5. Eﬀect of JCM-16021 on Mechanical Stimuli-Induced 5-
HT Release in PI-IBS Rats. To identify whether mechanical
stimuli (CRD) can induce excessive 5-HT release in PI-
IBS rats and the eﬀect of JCM-16021 on it, colonic 5-HT
content was evaluated in rats with or without AWR test.
As shown in Figure 5(a), after CRD application, the 5-HT
c o n t e n to fn o r m a lr a t sr e d u c e db y∼17% when compared to
that without CRD, but no statistical diﬀerences were found
betweenthesetwogroups;whileinPI-IBSrats,5-HTcontent
dramatically decreased by ∼68% after CRD application (P<
0.01). In pCPA-treated rats, CRD also induced marked
decrease of 5-HT content in PI-IBS rats (∼48%, P<0.05),
even though the baseline 5-HT content has been lowered
belowthenormallevel.AfterhighandmediumdoseofJCM-
16021 treatment, CRD did not induce signiﬁcant decreasesEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Eﬀect of JCM-16021 on mucosal SERT expression in PI-IBS rats. (a) shows the immunoﬂuorescence micrographs of (A1) negative
control (primary antibody omitted) and the positive SERT expressions (arrowhead) in the mucosa of (A2) normal rats, (A3) PI-IBS rats,
and (A4) high dose JCM-16021 treated rats (Scale bar, 200μm). Statistical analysis of intensity of SERT immunoreactivity is shown in (b).
Data are shown as mean ± S.E.M., n = 5p e rg r o u p .
∗∗P < 0.01 versus normal rats (t-test).
of 5-HT content (∼35% and ∼12%) when compared to
that without CRD application, suggesting that the treatment
of high and medium dose of JCM-16021 may attenuate
CRD-induced excessive 5-HT release in PI-IBS rats. Results
from electronic microsgraphs also showed that the secretory
granules within EC cells of PI-IBS rats were characterized by
clear secretory granules without cores or empty vesicles after
CRD application, indicating that there may be an excessive
5-HT release in PI-IBS rats after mechanical stimulation. In
high-dose JCM-16021-treated group, the secretory granules
within EC cells showed little empty vesicles when compared
to that of the PI-IBS rats (Figure 5(b)).
3.6. Eﬀect of JCM-16021 on Mucosal Cytokine Production in
PI-IBS Rats. As shown in Figure 6(a), the levels of TNF-α,
IFN-γ, IL-6, and IL-10 in the colonic mucosa of PI-IBS rats
were all signiﬁcantly decreased when compared to that of the
normal rats (P<0.05). High dose of JCM-16021 treatment
signiﬁcantly elevated the levels of TNF-α, IL-6, and IL-10,
but not IFN-γ, in PI-IBS rats, suggesting that JCM-16021
may modulate mucosal cytokines production in PI-IBS rats.
In pCPA-treated rats, the cytokine levels were not changed
when compared to that of the PI-IBS rats, indicating that 5-
HT depletion may have little eﬀect on cytokines production
of PI-IBS rats. As shown in Figure 6(b), even though the
detected cytokines were all decreased signiﬁcantly in PI-IBS
rats, the levels of Th1-related cytokines, TNF-α and IFN-
γ, were decreased more obviously (51% decrease in TNF-α,
42% decrease in IFN-γ) than others (14% decrease in IL-10,
19% decrease in IL-6).
4. Discussion
This study reveals that Chinese herbal formula JCM-16021
can dose-dependently attenuate visceral hyperalgesia in
TNBS-induced PI-IBS rats, and this eﬀect is mediated
through reducing colonic EC cell hyperplasia and 5-HT
availability. Moreover, our results also demonstrate that
JCM-16021 treatment can upregulate the decreased levels of
certain mucosal cytokines, especially the Th1-related cytoki-
nes,inPI-IBS,whichmaycontributetothetherapeuticeﬀect
of JCM-16021.
As a neurotransmitter, 5-HT plays an important role in
the perception and processing of nociceptive stimuli in the
gastrointestinal tract. It is well known that EC cell hyperpla-
sia and 5-HT hyperactivity are involved in the development
of visceral hypersensitivity [8–11]. Results from this study
showed that JCM-16021 treatment signiﬁcantly and dose-
dependently attenuated visceral hyperalgesia in PI-IBS rats,
and this eﬀect was concomitant with the decreased colonic
EC cell number and 5-HT availability. Treatment of pCPA,
the inhibitor of rate-limiting enzyme in 5-HT synthesis,
dramatically decreased colonic EC cell number and 5-HT
content in PI-IBS rats; and this eﬀect was consistent with
the attenuated visceral hyperalgesia in PI-IBS rats. All these
results indicate that the decreased EC cell number and
5-HT content induced by JCM-16021 treatment may be
responsible for the attenuated visceral hyperalgesia in PI-IBS
rats.
In this study, pCPA treatment resulted in dramatic
decrease of 5-HT content in PI-IBS rats. It is notable that8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀect of JCM-16021 on mechanical stimuli (CRD) induced 5-HT release in PI-IBS rats. (a) shows the statistical analysis of colonic
5-HT content in PI-IBS rats with or without CRD treatment. (b) shows the representative electron microsgraphs of EC cells and their
secretory granules (inset) from the (B1) normal rats, (B2) PI-IBS rats, and (B3) high dose JCM-16021 treated rats (×8900; inset: ×10000).
Activated EC cell is characterized by the clear secretory granules without cores (red arrow), or secretory granules with eccentric cores (red
arrowhead) in it. Data are shown as mean ± S.E.M., n = 5p e rg r o u p .
∗P < 0.05,
∗∗P < 0.01 versus the same group without CRD treatment
(t-test).
5-HT content in pCPA-treated rats was depleted seri-
ously, but no diﬀerences were found in visceral pain thresh-
old pressure between pCPA-treated rats and the normal
rats. We speculated that the remained 5-HT content, even
below the normal level, may be enough to fulﬁll the sensory
reﬂex [50] .M o r e o v e r ,a sp r o p o s e db yP .P .B e r t r a n da n dR .
L. Bertrand [51], the adaptive changes of gastrointestinal
tract to the environment and the overlapping functions of
numerous gastrointestinal hormones may explain why 5-HT
depletion in pCPA-treated rats did not cause marked change
in pain sensation. Interestingly, we also found that the EC
cell number in PI-IBS rats was signiﬁcantly decreased after
pCPA treatment. Current results cannot explain whether
such results are related with the reduced EC cell markers or
the total EC cell number. Further researches are needed.
It is well known that the main source of tissue 5-HT
content is consisted of synthesized 5-HT in EC cells and the
released 5-HT yet has not been taken up by SERT [9]. In
thisstudy,wefurtherinvestigatedtheeﬀectofJCM-16021on
TPH and SERT expression. The results indicated that colonic
TPH expression was increased in PI-IBS rats; and high
dose of JCM-16021 treatment signiﬁcantly reduced the TPH
expressioninPI-IBSrats,whichwereconsistentwellwiththe
alterations of EC cell number and 5-HT content. Moreover,
the expression of mucosal SERT was found signiﬁcantly
decreased in PI-IBS rats, and this result was in agreement
withthepreviousﬁndingswhichshowedthedecreasedSERT
expression in IBS patients [30] and IBS animal models [52].
High dose of JCM-16021 treatment did not show any eﬀect
on the decreased SERT expression in PI-IBS rats, indicating
that JCM-16021 treatment can decrease colonic EC cell
number, 5-HT content, and TPH expression, but not SERT
expression, in PI-IBS rats.
Knowing thattheexcessiveavailability of5-HTaremain-
ly come from increases of EC cell number, reduction of SERT
expression, or increases of stimuli-induced 5-HT release
[32], we further investigated the mechanical stimuli CRD-
induced 5-HT release in PI-IBS rats. Our results showed
that colonic 5-HT content and secretory granules within EC
cells were dramatically reduced in PI-IBS rats after CRD
application, suggesting thatthereisan excessive5-HT release
under mechanical stimulation in PI-IBS rats. Results fromEvidence-Based Complementary and Alternative Medicine 9
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Figure 6: Eﬀect of JCM-16021 on mucosal cytokines production in PI-IBS rats. Statistical graphs about mucosal cytokines production are
shown in (a). The rates of cytokines alteration are shown in (b). Data are shown as mean ± S.E.M., n = 5p e rg r o u p .
∗P < 0.05,
∗∗P < 0.01
versus normal rats, #P < 0.05 versus PI-IBS rats (t-test).
previous studies have shown that the postprandial 5-HT
content in IBS-D and PI-IBS patients were signiﬁcantly
increased [8, 53], and 5-HT metabolites/5-HT ratios in PI-
IBS patients were decreased [54]. These results provide the
evidences that there is an excessive 5-HT release in IBS
patients. As shown in this study, JCM-16021 treatment dose-
dependently attenuated CRD-induced reduction of 5-HT
content, and the secretary granules within EC cells were also
increasedinhigh-doseJCM-16021-treatedrats.Theseresults
indicate that JCM-16021 administration can attenuate the
mechanical stimuli-induced excessive 5-HT release in PI-IBS
rats.
To date, the underlying mechanisms of EC cell hyperpla-
siainPI-IBSareunknown,buttheyareconsideredhaveclose
correlationwithCD4+ Tlymphocytes,especiallytheTh1/Th2
balance [29, 32]. Previous studies have shown that EC cell
number and 5-HT content to the same infectious agent were
inﬂuenced by Th1o rT h2 cytokine predominance, and the
increased colonic EC cells and 5-HT content was found in
deﬁcient mice with impaired Th1 cytokine production [29].10 Evidence-Based Complementary and Alternative Medicine
Complemented with these ﬁndings, our results showed that
TNBS-induced PI-IBS rats had colonic EC cell hyperplasia,
and there is a dramatically reduced production of Th1-
related cytokines in the colonic mucosa of PI-IBS rats. This
study did not provide explanation why the levels of mucosa
cytokines in PI-IBS rats were all decreased, but this result
is consistent well with the ﬁndings from clinical studies,
which showed lowered levels of intestinal cytokines in IBS
patients [55]. May the lowered levels of mucosal cytokines of
IBS patients result from the suppressed immune response or
untriggered immune response after inﬂammation/infection?
IsthereanimbalancedTh1/Th2-relatedcytokinesproduction
inthecolonicmucosaofPI-IBSrats?Morestudiesareneeded
to explore these questions. In the present study, we found
that JCM-16021 treatment signiﬁcantly elevated the levels
of reduced cytokines, especially the Th1-related cytokines,
suggesting that JCM-16021 may have the potential eﬀect on
regulating immune system, which may be responsible for
the reduced EC cell hyperplasia in PI-IBS rats. It is well
known that most TCM remedies are formulated by using
individual herbs in combination. Under the guidance of
traditional theory, the diﬀerent herbs of certain formula are
thought to increase therapeutic eﬃcacy and reduce adverse
eﬀects simultaneously through multiple targets and biolog-
ical pathways [56]. To identify the main active constituents
of JCM-16021 that are responsible for the therapeutic eﬀects
observed in this study, further work is need.
In conclusion, the analgesic eﬀect of JCM-16021 on
TNBS-induced PI-IBS rats may be mediated via reducing
colonic EC cell hyperplasia and 5-HT availability, and the
elevatedproductionofmucosalTh1-relatedcytokinesTNF-α
mayberesponsibleforthealterationsinducedbyJCM-16021
in PI-IBS rats. The results from the present study give further
evidences for the analgesic eﬀect of JCM-16021 in IBS rats
also provide preliminary ﬁnding for the reduced production
ofTh1-relatedcytokinesinthecolonicmucosaofPI-IBSrats.
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